
price data provid thomson reuter
number may add due round
initi outperform -deal opportun
ise share under-valued view given compani lead asset zimura
set begin pivot clinic studi quarter larg estim
zimura rna aptam show posit result slow growth
lesion phase studi report last octob also investig
stargardt diseas data studi possibl
compani also build portfolio gene therapi candid first
program autosom domin retin pigmentosa adrp like enter
clinic late year
posit phase ga data lead way octob last year ise announc top-line
data ph trial zimura ga show zimura slow ga progress
monthli intravitr inject either mg dose level
treatment also well toler
detail come zimura pivot studi januari registration-en
trial zimura ga expect begin quarter ad clariti trial
design like top list compani upcom investor
symposium would expect larger studi one larg consist
prior studi regard inclusion/exclus criteria diseas measur
gene therapi portfolio earli get clinic year ise access
two aav-bas gene therapi program univers pennsylvania
univers florida first expect enter ph studi
vector contain shrna knock defect rho rna well
engin rho construct resist shrna intend restor
full rho function preclin result canin model point toward earli efficaci
preserv retin health see dual function rho knockdown
replac promis approach rare monogen inherit retin
diseas gene therapi program uf design
deliv function patient suffer best vitelliform macular
dystrophi ise could begin clinic studi final ise
seri sponsor research agreement univers massachusett
medic school minigen therapi program retin diseas use
compact variant function gene load aav vector three program
includ common subtyp leber congenit amaurosi
usher syndrom type
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
iver bio inc clinic stage biotechnolog compani focus discoveri develop novel
therapi retin diseas compani lead program zimura rna aptam current evalu
slow diseas progress geograph atrophi secondari dri age-rel macular dystrophi
stargardt diseas next pivot studi zimura ga slate start top-line result
ph trial zimura due april iver chang compani name ophthotech
corp rebrand effort compani transit strategi focu advanc pipelin gene
therapi candid compani first gene therapi program slate start ph studi rhodopsin-
mediat autosom domin retin pigmentosa rho-adrp compani second gene therapi
program expect begin clinic evalu address best diseas compani also minigen
program earli research stage leber congenit amaurosi usher syndrom type
sluggish enrol pivot
ga trial failur meet primari
endpoint ph studi gt
enrol pivot ga trial
proce accord plan
ph trial zimura
ph trial
start time
acceler patient enrol
pivot ga studi zimura best-
in-class ga market uptak
greater expect clinic
success multipl gt program
begin patient enrol pivot studi zimura
ga
top-lin data studi zimura
initi ph trial rho-adrp
multipl ww sale zimura
discount back ww
sale incid plu npv sale preval
clinic advanc zimura ga maintain
safeti profil potenti readthrough top-line trial
result zimura stargardt diseas punctual trial
start particularli gt program
posit ise posit readout recent
studi zimura ga compani fortifi
pipelin gene therapi candid team
leadership space
biotechnolog compani base
new york ny devot discoveri
develop novel therapi address retin
creat bluematrix
tabl content
pipelin catalyst summari
zimura geograph atrophi
market opportun model assumpt
zimura stargardt
autosom recess stargardt diseas ration zimura
gene therapi program
valuat financi model
tabl figur
figur pipelin mileston
figur beckman stage age-rel macular degener
figur ga impact visual function
figur simplifi scheme complement system
figur structur zimura
figur top-line result ph trial zimura geograph atrophi
figur least squar mean chang baselin cohort ph studi
figur least squar mean chang baselin cohort ph studi
figur select therapeut geograph atrophi target complement cascad
figur us market uptak wet drug eylea lucenti
figur lipofuscin accumul crry-inject mice
figur select investig candid autosom recess stargardt diseas
figur wt mutant suppress rho
pipelin catalyst summari
figur pipelin mileston
zimura geograph atrophi
macula measur mm diamet locat central area retina
light focus cornea len creat imag sent along optic
nerv brain macula respons fine vision necessari daili task
center macula fovea region maxim visual acuiti color sensit
macular diseas lead caus blind age-rel macular degener
progress retin diseas lead caus blind elderli popul
patient us often character drusen yellow lipid deposit
retina accumul stage accord beckman figur advanc
stage classifi either neovascular exud wet non-neovascular
atroph dri former involv angiogenesi leaki blood vessel back eye
lead scar macula respons amd-rel
fortun anti-vascular endotheli growth factor vegf agent effect option
four approv drug avail dri form geograph atrophi ga
retin pigment epithelium rpe layer choriocapillari becom thin progress
atrophi photoreceptor degener ensu lead vision impact ga lesion
manifest scotoma neg impact patient visual function though alway visual
acuiti figur diagnosi clinic done via ophthalmoscopi fundu photo
ophthalmologist observ drusen macular region atroph
risk factor ga includ age famili histori smoke cardiovascular diseas
current approv therapi dri amd/ga complement system inflamm
oxid stress propos contribut diseas estim preval
popul ga us ga incid
figur beckman stage age-rel macular degener
miller bagheri vavva
figur ga impact visual function
foveal spare lesion like exampl ga patient visual acuiti represent
ga patient field sight road sign
complement cascad part innat immun system repres highli conserv
mechan design provid host defens pathogen protein
blood role simplifi schemat complement system
recent review outlin figur system activ either via classic
pathway lectin pathway altern pathway classic pathway reli
bind natur antibodi neoepitop lectin pathway prompt damage-
associ molecular pattern damp recogn mannose-bind lectin mbl ficolin
fcn certain collectin cl altern altern pathway activ via hydrolysi
either spontan tick-ov surfac contact eventu pathway
converg convertas multiprotein assembl deem workhors
system product bioactiv fragment drive opson phagocytosi
inflamm immunomodul format membran attach complex
spur cell lysi complement cascad often tight control aberr activ
complement system age traumat insult genet dysregul may lead
differ diseas state therefor complement activ attract therapeut target
soliri eculizumab recombin human monoclon antibodi intend
inhibit cleavag anaphylatoxin develop alexion op laura chico
first complement-specif drug approv fda soliri administ
intraven approv four indic paroxysm nocturn haemoglobinuria
gmg neuromyel optica spectrum disord nmosd success soliri valid
complement-target therapi cinryz estearas inhibitor second fda-approv
therapeut target complement system hereditari angioedema ultomiri
second-gener soliri approv last pnh ahu
hand soliri biosimilar also current develop multipl late-stag
program target complement system across variou diseas
figur simplifi scheme complement system
mastello ricklin lambri
like soliri zimura target complement cascad howev unlik soliri zimura
pegyl stabil rna develop zimura select librari
optim rna-aptam use system evolut ligand exponenti enrich
selex approach evolv two stage stage one select bind specif
function activ stage two select enhanc affin aptam
result aptam bound kd nm inhibit pathway without
interact compon complement cascad aptam use clinic
investig contain cap kda
polyethylen glycol end figur develop rna aptam
therapeut come inher first rna aptam intrins
immunogen therefor potenti better-toler chronic therapi also rna aptam
synthes chemic potenti straightforward product first ph
studi investig zimura previous known ga initi juli
complet novemb zimura previous investig
combin lucenti anti-vegf agent wet discontinu
figur structur zimura
end ofoctob iver present top-line data random sham control ph
studi evalu zimura monotherapi treatment ga secondari
dri show mg mg zimura reduc mean rate ga growth
month figur enrol criteria encompass patient year old diagnosi
extrafov lesion thought grow faster studi two part part one gave
monthli intravitr inject mg zimura mg zimura sham
part two studi administ mg zimura mg zimura sham
analysi cohort includ mg- sham-treat patient studi part one
two cohort contain mg-treat patient sham-treat patient
part two
primari endpoint ph studi reduct ga growth rate measur
fundu autofluoresc mg zimura dose regimen patient experienc
reduct mean ga growth rate month figur compar
sham control cohort observ similar reduct ga growth rate
month lower p-valu figur secondari endpoint mean chang
best correct visual acuiti bcva baselin evalu use earli treatment
diabet retinopathi studi etdr letter score though given present ga effect
va unlik cohort saw improv letter mean chang
bcva low lumin bcva respect cohort patient
treat zimura monthli evalu efficaci
zimura well toler drug-rel advers event
inflamm
discontinu report endophthalm seriou ocular advers event
studi eye inject procedure-rel advers event frequent ocular
advers event report increas choroid neovascular cnv
zimura-tr group mg mg sham control group
figur top-line result ph trial zimura geograph atrophi
va visual acuiti mean chang ga area va base least squar mean mrm model
figur least squar mean chang baselin cohort ph studi
dose chang ga mm p-valuemean chang best correct va etdr differ etdr letter mean chang low lumin best correct va etdr differ etdr
figur least squar mean chang baselin cohort ph studi
thorough analys ph studi like present upcom retin
meet expect see updat treatment safeti later year given
time previou releas ise plan initi second pivot studi ga secondari
dri start identifi us intern site trial addit
detail design trial discuss compani upcom symposium
januari studi like close resembl prior studi evalu two
dose level mg mg zimura also expect enrol criteria select patient
extrafov lesion primari efficaci endpoint like safeti data
may extend month anticip ph studi complet reach
market year end
treatment option avail ga given larg grow popul
need develop therapi patient surprisingli drug develop space
receiv much attent target complement system central mani
effort figur highlight select candid investig ga provid addit
detail key program
apelli
apelli develop cyclic peptid conjug polyethylen glycol polym
target complement cascad two ph trial derbi oak
treatment ga octob compani paus dose patient due
manufactur lot caus non-infecti inflamm patient compani
resum dose patient expect complet enrol studi end
top-line result ph studi reduct ga growth rate month
baselin patient receiv monthli compar patient
treat sham growth rate reduct patient receiv everi
eye led patient discontinu liquid
formul requir reconstitut anticip mitig futur risk
importantli eye monthli report exud
eye treat eom develop exud eye treat sham
suggest chang cours wors
upstream implic protect role necessari innat adapt
immun mice model unlik retin pigmentosa model genet ablat
acceler structur function degener
believ ise target termin pathway effector downstream could
demonstr compar efficaci better safeti regardless base case
anticip receiv regulatori approv approv ahead ise
month phase clinic efficaci safeti result zimura
remain consist phase studi zimura could gain market share despit later
approv given exud risk associ
lampalizumab genentech nc
lampalizumab anti-factor antigen-bind fragment fab intend select inhibit
activ complement factor fd rate-limit proteas altern
complement result ph mahalo trial show reduct ga area
growth compar sham arm patient within subgroup complement factor cfi risk-
allel carrier appear greater reduct ga area growth howev two larg
ph trial chroma spectri fail show statist signific slow ga progress
patient treat mechan appear bypass fd
amplif convertas altern limit target factor
patient stratif instanc show benefit view play
larger role futur studi
soliri alexion op laura chico
alexion conduct ph complet studi soliri ga studi soliri
placebo- treat eye mean increas like due intraven deliveri
soliri oppos intravitr inject lead inadequ level drug retina
rpe
novarti
novarti studi intravitreal-deliv mab two-part ph studi
part use dose deliv everi part use singl
 dose reduc ga lesion growth rate compar sham-treat
patient ph studi monotherapi combin anti-properdin mab
alcon/novarti fail significantli reduc chang ga
lesion size growth baselin day compar sham primari endpoint
properdin gamma globulin protein complement cascad stabil
convertas altern pathway
cb op laura chico
catalyst cbio cb proteas preclin develop non-
human primat singl intravitr inject inhibit vitreou humor
day decemb enter global licens collabor agreement
cbio develop commerci cbio receiv up-front could
receiv mileston tier royalti
figur select therapeut geograph atrophi target complement cascad
sponsorproductmod eculizumab mab iv ph studi show ga growth rate reduct soliri tesidolumab mab ivt ph posit reduct ga lesion growth rate compar shamivericzimura avacincaptad pegol rna aptam ivt ph dose level reduct ga growth rate observ respect compar sham ph trial slate peptid ivt ph result reduct ga growth rate month baselin compar sham monthli every-other-month dose regimen respect current ph trial derbi oak expect enrol complet ivt preclinicalin non-human primat singl inject elimin vitreou humor day collabor announc dec droche/genentehlampalizumabfab ivt-ph mahalo trial reduct ga area growth compar sham two larg ph trial chroma spectri fail show ivt ph combin reduc chang ga lesion size growth baselin day factor bionis/rocheionis-fb-lrxantisens oligonucleotid sq ph ph studi healthi volunt demonstr toler reduc plasma fb ph studi began gene therapyph ph trial high dose cohort reduct ga growth rate month compar natur histori control opposit eye control ph trial initi intravitr iv intreven sq subcutan ga geograph atrophi mab monoclon antibodi fb factor membran attach complex
market opportun model assumpt
model assum approxim ga patient extrafov lesion without
neovascular diseas suitabl zimura therapi project zimura reach market
year end eu year later peak market penetr drug
price consist approv therapi wet model zimura sale
ga approach
evalu opportun ga obviou compar wet counterpart
four approv therapi eylea lucenti macugen beovu eylea
sale lucenti achiev albeit approv addit indic
eylea lucenti exceed us sale year respect figur beovu
brolucizumab receiv fda approv octob market novarti similar
zimura macugen pegaptanib discov nexstar pharmaceut anti-vegf
pegyl aptam current market bausch lamb macugen approv
figur us market uptak wet drug eylea lucenti
zimura stargardt
autosom recess stargardt diseas ration zimura
common form inherit macular degener preval
estim character progress vision loss
particularli central night vision often caus aberr copi atp-bind
cassett subfamili member gene protein also known rim
phosphatidylethanolamin pe schiff-bas conjug pe
cytoplasm leaflet disk membran lumen along transport function
catalyz isomer pe all-tran isom reduct all-trans-retinol
retinol dehydrogenas prevent excess accumul potenti toxic
bisretinoid compound vitamin byproduct atr-dim bisretinoid follow
abnorm accumul lipofuscin fatti yellow pigment
toxic retin cell underli macula lead cell damag phenotyp
manifest similar differ mutat
associ caus stargardt diseas missens mutat common
time diseas onset vari though typic appear late childhood earli adulthood
progress worsen time sixti percent patient diagnos age natur
histori studi determin growth rate effect lesion radiu
inappropri activ complement also associ
mous model higher level complement activ product observ
complement regulatori protein crp level reduc rpe cell compar
express wild-typ author attribut lipofuscin fluorophor
anoth studi mice test complement receptor protein crri deliv
subretin recombin adeno-associ viru aav vector reduc
complement factor well reduc bisretinoid pigment granul accumul compar
sham-treat mice figur result hinder photoreceptor
involv complement clinic similar diseas manifest ga point toward
zimura implic
figur lipofuscin accumul crry-inject mice
electron microscopi imag rpe yellow arrow indic electron-dens lipofuscin granul
histogram lipofuscin fraction area measur electron microscopi superior nasal
ise initi ph studi investig zimura patient autosom recess
patient must least two confirm pathogen mutat
gene bcva enrol enrol complet across
site februari sham control studi test zimura mg dose
iver report top-lin data anatom endpoint studi assess
mean rate chang area ellipsoid zone defect measur spectral domain-opt
coher tomographi sd-oct month
like ga approv therapi address oral drug candid
emixustat provid amen dose regimen target
lipofuscin format
accumul yet efficaci clinic remain seen gene therapi promis
option though challeng deliveri larg kb gene need overcom
stem cell therapi anoth option potenti rejuven replac damag rpe
zimura could well posit role complement diseas
describ industry-sponsor program describ also
highlight figur
alkeu pharmaceut
vitamin enrich deuterium stabl isotop carbon
intend slow dimer vitamin pigment format
lipofuscin preclin studi wild-typ rodent abl deter
current evalu ph trial daili oral administ drug
primari complet date anticip decemb
emixustat acucela inc
emixustat small molecul visual cycl modul inhibit isomeras complex prevent
accumul ph studi establish well-toler daili oral dose mg
dose-depend modul visual despit meet primari endpoint
ph trial ga acucela conduct ph trial emixustat
primari complet date anticip februari ph trial
complet novemb result report
sanofi
sanofi develop equin infecti anemia lentiviru gene therapi
program treatment howev ph trial
termin roch acquisit nightstar spark
respect preclin gene therapi program develop stargardt appli
genet technolog agtc op announc preclin program stargardt
data non-human primat model use hybrid dual aav vector system show full
length recombin human protein tissu sampl see note
figur select investig candid autosom recess stargardt diseas
model preval popul us eu use
similar price assumpt ga peak penetr project
world-wide sale zimura potenti opportun stand
non-gen therapi option could posit adjuv gene therapi
opportun zimura price target
ise develop small molecul inhibitor high affinity/specif high temperatur
requir serin peptidas protein protein implic retin diseas
includ ga inhibitor program acquir thorugh acquisit versant
ventur incept octob overexpress thought
contribut damag extracellular matrix bruch membran well upregul
complement contribut drusen format disrupt rpe cell inhibitor
subr ph sponsor decid stop develop oral ph determin safety/toler month daili dose effect diseas progress anticip complet dec biozimura ivt ph primari outcom sd-oct month top-line result estim oral ph primari outcom mean rate chang total area macular atrophi measur ph result report ph trial ga miss primari endpointsubr subretin inject ivt intravitr inject sd-oct spectral domain-opt coher tomogrphi
current preclin develop compani expect file ind ga
yet incorpor inhibitor program valuat see progress
program potenti upsid compani
retin pigmentosa rp common retin dystrophi character
degener rod photoreceptor symptom rp includ night-blind peripher visual
field constrict eventu loss central vision approxim
individu us eu rp among rp case mani exhibit autosom
domin ad inherit common case link mutat
rhodopsin gene rho rod visual pigment prototyp protein-coupl
receptor gpcr seven transmembran domain locat rod retina rhodopsin
compos scotopsin covalently-bound photoreact chromophor
respons absorpt photon isomer all-tran conform
order initi photorecept known tightli pack disc membran
estim rho molecul per photoreceptor allow function even low light
mutat rho lead protein misfold aggreg ubiquitin inclus bodi
accumul lead photoreceptor
design suppress mutant rhodopsin protein known rho mutat via
shrna express function replac rhodopsin protein packag singl
recombin vector deliv subretin figur shrna express
vector provid thorough knockdown rho mutant wt among
shrna evalu vitro yet effect engin contain four alter
nucleotid degenerate/wobbl posit target figur
preclin rho-mut adrp canin model construct
prevent retin degener dog challeng light-exposur acceler natur
cours diseas figur show construct abl preserv outer nuclear layer onl
thick treat area rod inner outer segment is/o signal detect
treat anim expos light knockdown dog rho rna also effect
week post inject transcript rna though rho protein level
lower canin rho level untreat area inject eye may due
impair codon prefer translat long-term assess vector stabil
dog light-challeng multipl time cone function stabl throughout
post inject period greater rod cone respons observ treat eye
time point assess electroretinogram erg
june ise enter agreement univers florida univers
pennsylvania develop commerci rho-adrp program ise also instig master
sponsor research agreement conduct preclin natur histori studi ise
plan initi ph studi rho-adrp like gain
insight program develop upcom compani event januari
collabor prof william beltran present among other
figur wt mutant suppress rho
model assum preval us popul rho-adrp patient anoth
patient eu clinic trial like open anticip reach
market peak penetr us similar price roch
luxturna installment-bas price model discount back project sale
discount rate add valuat
x-link retin pigmentosa hand gene therapi investig clinic
trial agtc awar one industry-sponsor trial adrp
on-going decemb proqr prqr nc dose first patient ph
trial investig lead asset adrp antisens
oligonucleotid target rho mutant mrna preserv wild-typ rho
frequent mutat rho account adrp case north
howev address mutant preval ic-
could address mani patient far behind prqr develop
gene therapi program
addit ise develop access multipl preclin gene therapi
program program earlier stage earliest ind file
expect earliest includ program valuat howev
watch program continu matur
best vitelliform macular dystrophi bvmd best diseas rare inherit retin diseas
aris mutat gene studi estim individu best
diseas ise estim patient across us encod
bestrophin regul chlorid ion traffic retin cell maintain homeostasi
subretin space dysfunct protein lead microdetach lesion
format macula current approv therapi treat best diseas ise
develop mutat independ gene therapi design deliv function
vector via subretin inject figur proof concept data canin model
ise expect initi ph trial current look
complet ind enabl activ natur histori studi program came second
seri gene therapi agreement univers pennsylvania univers florida
ise also enter seri sponsor research agreement univers
massachusett medic school earli minigen therapi program target retin
diseas minigen program look deliv compact variant function gene
wouldnt otherwis fit aav vector compani identifi three minigen program
date first design treat common subtyp leber congenit
amaurosi estim preval individu
preliminari proof-of-concept data mous model show retin structur function
preserv improv prolong function rescu ise exercis
option ww exclus right program aim identifi lead construct
second minigen program intend address autosom recess
stargardt diseas third minigen program ise investig usher
syndrom type relat nonsyndromat autosom recess retin pigmentosa
estim preval individu us eu combin
june ise enter strateg manufactur relationship paragon gene
therapi nc compani manufactur gmp-grade aav vector
gene therapi program paragon provid materi preclin
plan ph clinic trial aldevron contract suppli plasmid
valuat financi model
septemb ise cash cash equival decemb
compani rais addit equiti offer common share
greensho exercis pre-fund warrant per share research
develop expens expens
period last year gener administr expens modest
decreas net loss third quarter report
per share
initi coverag rate outperform price target sum-of-
part valuat base multipl estim ww zimura sale ga discount
back multipl estim ww zimura sale discount back
multipl estim ww sale incid popul rho-adrp
plu npv sale preval popul discount back valuat tabl
financi model
inhibitor product expens oper incom interest incom non-op incom incom incom incom ep share dilut share thousand except per share data
glenn sblendorio ceo presid
mr sblendorio initi join ise execut vice presid chief oper offic
chief offic januari mr sblendorio appoint presid mr
sblendorio serv member board prior join ise mr
sblendorio presid cfo medicin compani also held role
execut vice presid cfo mr sblendorio held execut vice presid cfo
posit eyetech pharmaceut mr sblendorio serv senior leadership role
hoffman-laroch year current serv board amicu
ba pace univers fairleigh dickinson
univers also graduat harvard busi school advanc manag
dr rezaei join ise senior vice presid appoint chief medic
offic dr rezaei also vitreoretin surgeon illinoi retina associ
associ professor rush univers medic center also presid channelr llc
on-line educ websit retina specialist dr rezaei receiv md univers
cologn medic school germani complet resid univers chicago
dr gao appoint chief strategist gene therapi novemb dr gao also
current serv presid american societi gene cell therapi also co-
director li weibo institut diseas research director hora gene therapi center
viral vector professor univers massachusett medic school
senior editor gene cell therapi book seri associ editor signal transduct
target therapi editori board multipl gene therapi y/virolog journal
publish research paper hold patent patent pend
dr scaria join ise novemb chief scientif offic prior appoint
ise dr scaria vice presid head ophthalmology/gen edit casebia
therapeut also held previou role sanofi genzym head gene therapi
research senior director gene therapy/ophthalmolog among posit dr scaria
receiv degre univers mumbai medic biochemistri ph
molecular biolog indiana univers school medicin postdoctor fellow
saint loui univers school medicin senior fellow medic genet univers
mr carrol appoint cfo ise april initi join ise
senior vice presid financ prior ise mr carrol work medicin compani
senior vice presid chief account offic mr carrol also prior experi
director commerci financ genentech execut director financ novarti
senior manag financ bristol-my squibb receiv ba degre econom
account french ursinu colleg financ rutger univers
mr carrol also certifi public account
mr westbi appoint chief oper offic ise retain role
senior vice presid held sinc mr westbi initi join ise known
ophthotech senior director project manag also serv vice
presid program manag busi oper compani prior join
ise mr westbi director project allianc manag pharmasset inc
also spent time eyetech pharmaceut director allianc project manag
senior consult tunnel consult mr westbi receiv bs appli physic
suni genesco ms engin manag drexel univers
ms harrison initi join ise chief oper offic serv chief
clinic oper offic sinc prior join ise ms harrison senior vice
presid clinic develop eyetech osi ms hoffman also director clinic
oper hoffmann-la roch receiv ba biolog hofstra univers
manag manhattan colleg
ms sheehan join ise vice presid human resourc appoint
senior vice presid chief offic prior join ise ms
sheehan head electron system divis parker hannifin ms
sheehan also serv associ director osi pharmaceut ms
sheehan receiv ba psycholog ms human resourc manag hofstra
friedman et al preval age-rel macular degener unit
miller bagheri vavva advanc age-rel macular degener
understand therapi us ophthalm
genentech avail http //www gene com/patients/disease-
nebbioso et al therapeut approach intravitr inject geograph
atrophi secondari age-rel macular degener current drug potenti
geograph atrophi eyewiki avail http //eyewiki aao org/geograph atrophi
lesli new view complement scienc
mastello ricklin lambri clinic promis next-gener
applic promis new horizon current medicin chemistri
bieseck dihel enney bendel deriv rna aptam inhibitor
drolet green gold janjic aptam ocular
epstein kurz complement bind aptam agent use
treatment ocular disord
zhou rossi aptam target therapeut current potenti challeng
liao et al complement inhibitor pegcetacoplan geograph atrophi
secondari age-rel macular degener random phase trial
compon requir protect innat adapt immun larval
strongyloid stercorali mice immunol
silverman wang zhao wong
microgli clearanc protect photoreceptor retin pigmentosa
holz et al efficaci safeti lampalizumab geograph atrophi due age-
relat macular degener chroma spectri phase random clinic trial
irmscher et al kallikrein cleav activ complement innat immun
yehoshua et al system complement inhibit eculizumab geograph
atrophi age-rel macular degener complet studi ophthalmolog
stargardt macular degener genet refer nih avail
molday zhong quazi role photoreceptor transport
lipid transport stargardt macular degener biochimica et biophysica
acta molecular cell biolog lipid
quazi molday atp-bind cassett transport chemic
isomer protect photoreceptor cell toxic accumul excess
leni et al express retin pigment epithelium
implic stargardt macular degener proc natl
allikmet et al mutat stargardt diseas gene abcr age-rel macular
 sun nardini prior del natur histori autosom
recess stargardt diseas untreat eye systemat review meta-analysi
study- individual-level data ophthalmolog
radu et al complement system dysregul inflamm retin
pigment epithelium mous model stargardt macular degener biol
leni et al complement modul retin pigment epithelium rescu
photoreceptor degener mous model stargardt diseas proc natl
retina today seek therapi stargardt macular dystrophi july/august
avail
kaufman washington deuterium enrich vitamin
posit slow format detriment vitamin dimer wild-typ rodent
lewin rossmil mao gene augment adrp mutat rho
athanasi et al molecular cellular basi rhodopsin retin pigmentosa
reveal potenti strategi therapi prog retin januari
mani rhodopsin molecul rod cell avail
saliba munro luthert cheetham cellular fate mutant
rhodopsin qualiti control degrad aggresom format
cideciyan et al mutation-independ rhodopsin gene therapi knockdown
replac singl aav vector proc natl
giannelli et al select target rhodopsin mutant allel
treat retin pigmentosa intravitr deliveri mol
ziviello et al molecular genet autosom domin retin pigmentosa adrp
comprehens studi italian famili genet
microdetach modul light exposur proc natl
multipl ww sale zimura discount back ww sale incid
plu npv sale preval discount back
risk attain price rate
zimura may fail demonstr clinic efficaci and/or adequ safeti pivot studi ga gain fda approv even
zimura approv ga regul market uptak drug may limit due market competit cost physician/
patient prefer factor finit patent protect may see earli competit gener caus zimura market
potenti short-liv miss estim launch also ise gene therapi program may fail ind submiss
demonstr appropri safety/efficaci earli clinic studi
david nierengarten jeffrey la rosa matthew barcu certifi view express report accur reflect
person opinion directli indirectli receiv compens payment connect
specif recommend view contain report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
januari
januari
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
